Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Atossa Therapeutics

18/03/2024 11:04

* Atossa Therapeutics Inc  ATOS.OQ   ATOS.O  is expected
to show
no change in quarterly revenue when it reports  results on March
20 (estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Atossa Therapeutics Inc
is for
a loss of 6 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Atossa
Therapeutics Inc is $4.00​, above​ its last closing price
of $1.29. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.07       -0.07      -0.05     Beat    28.6
 Jun. 30 2023              -0.06      -0.08     Missed  -33.3
 Mar. 31 2023              -0.06      -0.05     Beat    16.7​
 Dec. 31 2022              -0.06      -0.06     Met     0
 ​​Sep.                    -0.06      -0.06     Met     0
 30 2022                                                
 Jun. 30 2022              -0.06      -0.05     Beat    16.7​
 Mar. 31 2022  -0.04       -0.05      -0.04     Beat    20
 Dec. 31 2021  -0.04       -0.04      -0.04     Met     11.1
 This summary was machine generated March 18 at 11:04 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)